Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof
The present disclosure is directed to novel crystalline forms of ozanimod and ozanimod hydrochloride, as well as preparation method thereof. Said crystalline forms of ozanimod and ozanimod hydrochloride can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis. The crystalline forms of the present disclosure have one or more advantages in solubility, melting point, stability, dissolution, bioavailability and processability and provide new and better choices for the preparation of ozanimod drug product, and are very valuable for drug development.
1. A crystalline Form CS1 of ozanimod, wherein the X-ray powder diffraction pattern shows characteristic peaks at 2theta values of 12.1°±0.2°, 10.4°±0.2° and 4.2°±0.2° using CuKα radiation.
2. The crystalline Form CS1 of ozanimod according to claim 1 , wherein the X-ray powder diffraction pattern shows 1 or 2 or 3 characteristic peaks at 2 theta values of 7.4°±0.2°, 24.3°±0.2° and 17.7°±0.2° using CuKα radiation.
3. The crystalline Form CS1 of ozanimod according to claim 1 , wherein the X-ray powder diffraction pattern shows 1 or 2 or 3 characteristic peaks at 2 theta values of 12.8°±0.2°, 21.5°±0.2° and 18.2°±0.2° using CuKα radiation.
4. A process for preparing crystalline Form CS1 of ozanimod according to claim 1 , wherein the process comprises method 1) or method 2),
1) suspending ozanimod hydrochloride into a solvent selected from an alcohol, a ketone, an ester, and a nitrile and stirring, adding 1.0 to 1.5 equivalent of sodium hydroxide solution to the suspension to obtain a clear solution; after stirring the clear solution at room temperature, precipitating a white solid from the solution, isolating, drying the solid to obtain a white solid which is Form CS1 of ozanimod; wherein said stirring time is at least 0.5 hour; or
2) suspending ozanimod into an alcohol and stirring, isolating and drying the solid to obtain Form CS1 of ozanimod; wherein said stirring time is at least 0.5 hour,
wherein said alcohol in method 1) or method 2) is methanol; said ketone is acetone; said ester is isopropyl acetate; said nitrile is acetonitrile.
5. A crystalline Form CS2 of ozanimod, wherein the X-ray powder diffraction pattern shows characteristic peaks at 2 theta values of 23.2°±0.2°, 18.5°±0.2° and 13.3°±0.2° using CuKα radiation.
6. The crystalline Form CS2 of ozanimod according to claim 5 , wherein the X-ray powder diffraction pattern shows 1 or 2 or 3 characteristic peaks at 2 theta values of 15.9°±0.2°, 30.0°±0.2° and 14.2°±0.2° using CuKα radiation.
7. The crystalline Form CS2 of ozanimod according to claim 5 , wherein the X-ray powder diffraction pattern shows 1 or 2 or 3 characteristic peaks at 2 theta values of 4.0°±0.2°, 26.5°±0.2° and 17.7°±0.2° using CuKα radiation.
8. A process for preparing crystalline Form CS2 of ozanimod according to claim 5 , wherein the process comprises method 1) or method 2),
1) Preparing the crystalline Form CS2 by heating Form CS1 of ozanimod of which the X-ray powder diffraction pattern shows characteristic peaks at 2 theta values of 12.1°±0.2°, 10.4°±0.2° and 4.2°±0.2° using CuKα radiation to 100-130° C.; or
2) Suspending ozanimod into a solvent selected from a nitrile, a ketone, an ester, an aromatic hydrocarbon, a cyclic ether, and water, or a mixture of solvents selected from an alcohol and water, a ketone and water, an amide and water, stirring, isolating to obtain a solid, and drying the solid to obtain Form CS2 of ozanimod; wherein said stirring time is at least 0.5 hour.
9. A crystalline Form CS3 of ozanimod, wherein the X-ray powder diffraction pattern shows characteristic peaks at 2 theta values of 4.4°±0.2°, 13.0°±0.2°, 26.0°±0.2° and 11.0°±0.2° using CuKα radiation.
10. The crystalline Form CS3 of ozanimod according to claim 9 , wherein the X-ray powder diffraction pattern shows 1 or 2 or 3 characteristic peaks at 2 theta values of 7.8°±0.2°, 23.2°±0.2° and 17.0°±0.2° using CuKα radiation.
11. The crystalline Form CS3 of ozanimod according to claim 9 , wherein the X-ray powder diffraction pattern shows 1 or 2 characteristic peaks at 2 theta values of 13.7°±0.2° and 24.1°±0.2° using CuKα radiation.
12. A process for preparing crystalline Form CS3 of ozanimod according to claim 9 , wherein the process comprises adding ozanimod into a solvent selected from an alcohol, a nitrile, dichloromethane, an ester, or a sulfoxide, filtering, evaporating the filtrate, and collecting the solid to obtain Form CS3 of ozanimod, wherein said alcohol is methanol; said nitrile is acetonitrile; said ester is isopropyl acetate; said sulfoxide is dimethyl sulfoxide.
13. A crystalline Form CS5 of ozanimod, wherein the X-ray powder diffraction pattern shows characteristic peaks at 2 theta values of 4.3°±0.2°, 6.8°±0.2° and 16.4°±0.2° using CuKα radiation.
14. The crystalline Form CS5 of ozanimod according to claim 13 , wherein the X-ray powder diffraction pattern shows 1 or 2 or 3 characteristic peaks at 2 theta values of 21.6°±0.2°, 8.5°±0.2° and 13.6°±0.2° using CuKα radiation.
15. The crystalline Form CS5 of ozanimod according to claim 13 , wherein the X-ray powder diffraction pattern shows 1 or 2 or 3 characteristic peaks at 2 theta values of 13.0°±0.2°, 25.0°±0.2° and 26.0°±0.2° using CuKα radiation.
16. A process for preparing crystalline Form CS5 of ozanimod according to claim 13 , wherein the process comprises adding the solid of ozanimod into a cyclic ether, filtering, evaporating the filtrate and collecting the solid to obtain Form CS5 of ozanimod, wherein said cyclic ether is 2-methyltetrahydrofuran.
17. A crystalline Form CS6 of ozanimod, wherein the X-ray powder diffraction pattern shows characteristic peaks at 2 theta values of 4.4°±0.2°, 24.5±0.2°, 26.5°±0.2° and 13.8°±0.2° using CuKα radiation.
18. The crystalline Form CS6 of ozanimod according to claim 17 , wherein the X-ray powder diffraction pattern shows 1 or 2 characteristic peaks at 2 theta values of 13.0°±0.2° and 25.4±0.2° using CuKα radiation.
19. The crystalline Form CS6 of ozanimod according to claim 17 , wherein the X-ray powder diffraction pattern shows 1 or 2 or 3 characteristic peaks at 2 theta values of 8.9°±0.2°, 13.4°±0.2° and 11.0°±0.2° using CuKα radiation.
20. A process for preparing crystalline Form CS6 of ozanimod according to claim 17 , wherein the process comprises adding solid of ozanimod into a solvent selected from a ketone and chloroform, filtering, evaporating the filtrate and collecting the solid to obtain Form CS6 of ozanimod, wherein said ketone is acetone.
21. A pharmaceutical composition, wherein said pharmaceutical composition comprises a therapeutically effective amount of crystalline Form CS2 of ozanimod according to claim 5 , and a pharmaceutically acceptable carrier, a diluent or an excipient.
22. A method of treating ulcerative colitis, comprising administering to a patient in need thereof a therapeutically effective amount of crystalline Form CS2 of ozanimod according to claim 5 .
23. A method of treating multiple sclerosis, comprising administering to a patient in need thereof a therapeutically effective amount of crystalline Form CS2 of ozanimod according to claim 5 .
24. A pharmaceutical composition, wherein said pharmaceutical composition comprises a therapeutically effective amount of crystalline Form CS1 of ozanimod according to claim 1 , and a pharmaceutically acceptable carrier, a diluent or an excipient.
25. A method of treating ulcerative colitis, comprising administering to a patient in need thereof a therapeutically effective amount of crystalline Form CS1 of ozanimod according to claim 1 .
26. A method of treating multiple sclerosis, comprising administering to a patient in need thereof a therapeutically effective amount of crystalline Form CS1 of ozanimod according to claim 1 .
27. A pharmaceutical composition, wherein said pharmaceutical composition comprises a therapeutically effective amount of crystalline Form CS3 of ozanimod according to claim 9 , and a pharmaceutically acceptable carrier, a diluent or an excipient.
28. A method of treating ulcerative colitis, comprising administering to a patient in need thereof a therapeutically effective amount of crystalline Form CS3 of ozanimod according to claim 9 .
29. A method of treating multiple sclerosis, comprising administering to a patient in need thereof a therapeutically effective amount of crystalline Form CS3 of ozanimod according to claim 9 .
30. A pharmaceutical composition, wherein said pharmaceutical composition comprises a therapeutically effective amount of crystalline Form CS5 of ozanimod according to claim 13 , and a pharmaceutically acceptable carrier, a diluent or an excipient.
31. A method of treating ulcerative colitis, comprising administering to a patient in need thereof a therapeutically effective amount of crystalline Form CS5 of ozanimod according to claim 13 .
32. A method of treating multiple sclerosis, comprising administering to a patient in need thereof a therapeutically effective amount of crystalline Form CS5 of ozanimod according to claim 13 .
33. A pharmaceutical composition, wherein said pharmaceutical composition comprises a therapeutically effective amount of crystalline Form CS6 of ozanimod according to claim 17 , and a pharmaceutically acceptable carrier, a diluent or an excipient.
34. A method of treating ulcerative colitis, comprising administering to a patient in need thereof a therapeutically effective amount of crystalline Form CS6 of ozanimod according to claim 17 .
35. A method of treating multiple sclerosis, comprising administering to a patient in need thereof a therapeutically effective amount of crystalline Form CS6 of ozanimod according to claim 17 .
36. A process for preparing crystalline Form CS3 of ozanimod according to claim 9 , wherein the process comprises adding ozanimod into a mixture of glycol dimethyl ether and water, filtering, evaporating the filtrate, and collecting the solid to obtain Form CS3 of ozanimod.